Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Rilonacept

Abstract

In February 2008, rilonacept (Arcalyst; Regeneron), an interleukin 1 blocker, was approved by the US FDA for the treatment of a group of rare autoinflammatory diseases known as cryopyrin-associated periodic syndromes.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The cryopyrin inflammasome and CAPS.

References

  1. Shinkai, K. et al. Cryopyrin-associated periodic syndromes and autoinflammation. Clin. Exp. Dermatol. 33, 1–9 (2008).

    CAS  PubMed  Google Scholar 

  2. Drenth, J. P. H. & van der Meer, J. W. M. The inflammasome — a linebacker of innate defense. N. Engl. J. Med. 355, 730–732 (2006).

    Article  CAS  Google Scholar 

  3. Hoffman, H. M. et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle–Wells syndrome. Nature Genet. 29, 301–305 (2001).

    Article  CAS  Google Scholar 

  4. Agostini, L. et al. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle–Wells autoinflammatory disorder. Immunity 20, 319–325 (2004).

    Article  CAS  Google Scholar 

  5. Hawkins, P. N. et al. Interleukin-1-receptor antagonist in the Muckle–Wells syndrome. N. Engl. J. Med. 348, 2583–2584 (2003).

    Article  Google Scholar 

  6. Hoffman, H. M. et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364, 1779–1785 (2004).

    Article  CAS  Google Scholar 

  7. Economides, A. N. et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nature Med. 9, 47–52 (2003)

    Article  CAS  Google Scholar 

  8. Food and Drug Administration. FDA labelling information [online], (2008).

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

Hal M. Hoffmann is a consultant for Regeneron.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoffman, H., Yasothan, U. & Kirkpatrick, P. Rilonacept. Nat Rev Drug Discov 7, 385–386 (2008). https://doi.org/10.1038/nrd2579

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2579

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing